Compare FPF & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FPF | DBVT |
|---|---|---|
| Founded | 2013 | 2002 |
| Country | United States | France |
| Employees | N/A | 90 |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 948.8M |
| IPO Year | 2013 | 2014 |
| Metric | FPF | DBVT |
|---|---|---|
| Price | $17.66 | $13.68 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $32.04 |
| AVG Volume (30 Days) | 90.0K | ★ 275.2K |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | ★ 8.08% | N/A |
| EPS Growth | N/A | ★ 10.26 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $5,636,000.00 |
| Revenue This Year | N/A | $35.04 |
| Revenue Next Year | N/A | $2,360.78 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 35.77 |
| 52 Week Low | $17.21 | $8.51 |
| 52 Week High | $19.75 | $26.19 |
| Indicator | FPF | DBVT |
|---|---|---|
| Relative Strength Index (RSI) | 36.96 | 32.26 |
| Support Level | $17.58 | $12.63 |
| Resistance Level | $18.26 | $14.68 |
| Average True Range (ATR) | 0.16 | 0.87 |
| MACD | -0.03 | -0.17 |
| Stochastic Oscillator | 14.29 | 11.88 |
First Trust Inter Dur Pref& Income Fund is a diversified, closed-end management investment company. Its primary investment objective is to seek a high level of current income. Further, it has a secondary objective of capital appreciation. The Fund invests in the traditional preferred securities, hybrid preferred securities, floating rate & fixed-to-floating rate preferred securities, debt securities, convertible securities, and contingent convertible securities issued by U.S. and non-U.S. companies. Its investment portfolio includes industries such as Banks, Insurance, Capital Markets, Electric Utilities, Oil, Gas & Consumable Fuels, Food Products, and others.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.